End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.28 CNY | -1.44% | +1.88% | -5.08% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.08% | 2.85B | C | ||
-2.61% | 88.47B | A- | ||
+3.55% | 40.71B | A- | ||
-14.04% | 32.43B | B- | ||
+55.89% | 24.28B | A | ||
-15.93% | 15.52B | C | ||
-41.29% | 12.17B | B | ||
-15.58% | 12.01B | B- | ||
-11.75% | 12B | D+ | ||
+7.87% | 8.87B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600867 Stock
- Ratings Tonghua Dongbao Pharmaceutical Co., Ltd.